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AbstrAct
Unique molecular properties of species D adenoviruses (Ads)—the most diverse 
yet underexplored group of Ads—have been used to develop improved gene vectors. 
The low seroprevalence in humans of adenovirus serotype 43 (Ad43), an otherwise 
unstudied species D Ad, identified this rare serotype as an attractive new human gene 
therapy vector platform. Thus, in this study we wished to assess biological properties 
of Ad43 essential to its vectorization. We found that (1) Ad43 virions do not bind blood 
coagulation factor X and cause low random transduction upon vascular delivery; (2) 
they clear host tissues more quickly than do traditionally used Ad5 vectors; (3) Ad43 
uses CD46 as primary receptor; (4) Ad43 can use integrins as alternative primary 
receptors. As the first step toward vectorization of Ad43, we demonstrated that the 
primary receptor specificity of the Ad43 fiber can be altered to achieve infection 
via Her2, an established oncotarget. Whereas this modification required use of the 
Ad5 fiber shaft, the presence of this domain in chimeric virions did not make them 
susceptible for neutralization by anti-Ad5 antibodies.
INtrODUctION
Most adenovirus(Ad)-based vectors for human gene 
therapy developed to date were derived from human Ad 
serotype 5 (Ad5)—the best studied of all types. However, 
Ad vector development benefitted significantly from studies 
of Ad serotypes other than Ad5. These studies identified 
the essential differences in molecular properties between 
various Ads and were instrumental in addressing major 
limitations of Ad5-based vectors, including these vectors’ 
lack of target receptor specificity, inefficient transduction 
of many types of human cells, unfavorable biodistribution 
in vivo, and neutralization by anti-Ad5 antibodies (Abs) 
found in many humans. This research yielded important 
knowledge on the structure of the receptor-binding sites 
within Ads fiber proteins [1], the significance of fiber length 
[2] and flexibility for efficient transduction [3], differential 
interaction of various Ads’ hexons with blood coagulation 
factors [4–6] and liver macrophages [7, 8], and great 
variations in levels of neutralizing Abs in humans against 
various Ad serotypes [9]. As a result, important practical 
milestones in vector development have been achieved, such 
as the design of Ad vectors ablated of undesirable native 
receptor specificities [1], reduced uptake by non-target 
tissues [5, 10, 11], reduced toxicity [11, 12], and altered 
immunogenicity profiles [13]. Despite these successes, 
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Ad vectors better suited for gene therapy are yet to be 
developed, thus warranting the exploration of currently 
uncharacterized Ad serotypes.
Several improvements of Ad vectors resulted 
from studies of species D Ads [5, 6, 10, 13], the most 
diverse and largely underexplored Ad species. Although 
complete genomic sequences are available for more than 
40 members of this species (summarized at http://www.
vmri.hu/~harrach/AdVtaxlong.htm), few of these Ads 
have been studied in significant detail to support their 
use for therapeutic gene delivery. Primary receptors have 
been identified for only a few species D Ads [14–17]; no 
systematic studies have been performed on these Ads’ 
intracellular trafficking, assembly, and maturation; and 
data on these Ads’  biodistribution and tropism in vivo 
are similarly limited [6, 7]. Only a few of these Ads have 
been tested as vectors [14, 18–21], and no attempts to 
alter these vectors’ natural tropism in order to target gene 
delivery have been reported. 
Previous report on low seroprevalence in humans 
of Ad serotype 43 (Ad43) [9]—an otherwise unexplored 
member of species D—makes this virus a candidate as an 
alternative platform for the generation of vectors capable 
of evading neutralization by pre-existing anti-Ad5 Abs 
found in most humans [9]. Thus, in this study we wished to 
take a first look at the important aspects of Ad43 biology 
directly relevant to future vectorization of this yet virtually 
unknown virus. To this end, we sequenced and annotated 
the genome of Ad43, compared its structure with those of 
other Ads, ascertained the biodistribution of intravenously 
injected Ad43 virions, designed a plasmid-based system 
that facilitates molecular manipulations with Ad43 genome, 
identified Ad43’s primary receptors, and successfully 
modified the primary receptor specificity of Ad43 fiber 
to enable infection via human epidermal growth factor 
receptor type 2 (Her2), a recognized oncotarget. The results 
of this work lay the foundation for future development of 
Ad43-based vectors suitable for human gene therapy.
rEsULts
Owing to the lack of blood coagulation factor X 
(FX) binding by the Ad43 hexon, intravenously 
injected Ad43 vector causes significantly reduced 
off-target transduction
The global pairwise alignment of the Ad43 genome 
(GenBank accession number KC529648) with genomes of 
other species D Ads revealed a high homology (93–98%), 
whereas its alignment with genomes of species A, B, C, E, 
and F Ads showed much lower homology (40% to 70%). 
The E3 region and genes of the major capsid proteins of 
Ad43—the penton base, hexon, and fiber—diverged the 
most from those of all other Ad serotypes except Ad28 
(Supplementary Figure S1 and Table S1). Because these 
major capsid proteins play essential roles in Ads’ infection 
[5, 22, 23], we studied the effects of this divergence on 
Ad43 tropism.
Our sequencing data revealed that the Ad43 hexon 
does not contain amino acids (aa) whose presence 
in the Ad5 hexon enables binding of FX, leading to 
undesired, off-target liver transduction by Ad5 vectors 
on intravascular delivery [6, 10] (Figure 1). Interestingly, 
however, the Ad43 hexon’s hypervariable region (HVR) 
5 contains a TDT-tripeptide whose presence in HVRs 
2, 3, and 7 in other Ad hexons strongly correlates with 
FX binding [5, 6] (Figure 1). Our assessment of Ad43 
interaction with FX by surface plasmon resonance showed 
no measurable association whereas an interaction between 
Ad5 and FX is apparent (Figure 2A).
This lack of association between FX and Ad43 
predicted negligible hepatic transduction by an 
intravenously administered Ad43. Indeed, the patterns of 
liver transduction in mice injected with Ad43TL vector 
and in mice injected with Ad5TL vector—the E1-deleted 
Ads each expressing a genetic fusion of the herpes 
simplex virus thymidine kinase and firefly luciferase 
Figure 1: Alignment of Ad43 hexon HVrs 2, 3, 5, and 7 with HVrs of FX-binding hexons. The Ad5 hexon amino acids 
residues in HVR5 and HVR7 involved in binding FX [10] are highlighted in gray; none of them is present in the Ad43 hexon. Shown in bold 
red are the TET tripeptide (in the Ad5 hexon’s HVR7) previously implicated in FX binding [5] and its homologue, TDT, whose presence 
in HVRs of other Ads hexons correlates strongly with reported binding to FX. Of the human Ad serotypes whose binding to FX was tested 
and confirmed [5], seven contain TDT in their hexons. Six of these Ads are shown below the dashed line.
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(TL)—differed dramatically: on average, transgene 
reporter bioluminescence activity in Ad43TL-injected 
mice was at background level and 2.4 × 104 times lower 
than such activity in Ad5TL-injected animals (Figure 2B). 
The measurements of luciferase activity in the lysates of 
livers of Ad-injected mice collected 24 h later revealed 
a 1.3 × 105-fold difference (Figure 2C). Notably, 
transduction of all other tested organs was significantly 
lower in mice injected with Ad43TL than in Ad5TL-
injected animals (Figure 2C and Table 1).
Ad43 virions quickly clear non-target tissues
In vivo distribution patterns and temporal dynamics 
of these patterns are essential parameters of vector 
clearance by the host. To determine them for Ad43, we 
measured the copy numbers of viral genomes in tissues 
collected from mice 1, 24, and 72 h after tail vein 
injections with Ad43TL and control Ad5TL. One hour 
after injection (Figure 2D), the profiles of biodistribution 
for both Ads were similar. Differences were seen only in 
the spleen (p = 0.0056) and in the kidneys (p = 0.0012), 
in which Ad43 was found at level 2.6 times and 8.5 times 
higher than that of Ad5, respectively. Despite the drastic 
difference seen in the liver transduction patterns, the levels 
of both Ads in the liver at this time point were very similar 
and much higher than in any other tissue (p-values for 
Ad43 and Ad5 are < 0.0004 and < 0.0003, respectively).  
Notably, over the next 24 h and 72 h, the Ad43 
genome copy numbers decreased faster than did those 
of Ad5 genome (p < 0.0001). In particular, over the 
course of the 24 h period after injection, the amount of 
Ad DNA in the liver had decreased dramatically for both 
Ads and remained unchanged for each vector 48 h later. 
Importantly, however, the magnitude of this change was 
substantially different for the two compared Ads. The Ad5 
DNA content in the liver decreased 15 times at the 24 h 
time point but remained higher than in any other tissue. 
The level of Ad43 DNA in the liver decreased 163 times 
and became indistinguishable from that in the spleen 
(p = 0.4861), and only slightly higher than that in the 
kidneys (p = 0.0415), in which Ad43 DNA also decreased 
substantially relative to the 1 h time point values. The 
amount of Ad43 DNA decreased significantly between the 
1 h and 24 h time points for all tissues: the liver, spleen, 
lungs, heart, and kidneys (all p-values < 0.02). These 
decreases were significantly larger for Ad43 than for Ad5 
in all tested tissues (all p-values < 0.02).
Comparison of the data for the 24 h and 72 h time 
points revealed further decreases in Ad43 DNA content 
in the spleen (p = 0.0480) and kidneys (p = 0.0282), and 
in Ad5 DNA content in the spleen (p = 0.0485), heart 
(p = 0.0416), and lungs (p = 0.0021). Although the Ad43 
genome copy number in the kidney gradually decreased 
between 1 h and 72 h, the Ad5 DNA copy number stayed 
relatively constant over time.
Ad43 exploits two types of receptors for infection
Most Ads attach to their primary receptors on 
cells using the knob domain of the fiber protein. Several 
receptors for species D Ads, such as CD46 [14, 19, 20], 
sialic acid [24, 25], and coxsackievirus and Ad receptor 
(CAR) [26, 27], are known. To identify the primary 
receptor(s) for Ad43, we first tested whether Ad43 uses 
CD46 for infection. To this end, CD46-negative CHO cells 
and CHO-C2 cells that express the C2 isoform of CD46 
were infected with Ad43TL and Ad35TL (used here as 
positive control because of Ad35’s known specificity for 
CD46 [28]). Prior to infection, the cells were incubated 
with the recombinant Ad35 fiber knob domain—a strong 
competitive blocker of CD46. As anticipated, Ad35TL 
transduced CHO-C2 cells much more efficiently than it 
transduced CHO cells (49-fold), and the knob inhibited 
Ad35 transduction of CD46-positive cells very effectively, 
whereas no inhibition was seen in control CHO cells 
(Figure 3A). A similar dependence on CD46 was also seen 
for Ad43TL: CHO-C2 cells were transduced by Ad43TL 
5.3-fold more efficiently than were CHO cells, thus 
supporting the use of CD46 by Ad43. Notably, although 
Ad43TL transduced CHO-C2 cells less efficiently than did 
Ad35TL, inhibition of this transduction by the Ad35 fiber 
knob was also lower (45% vs 90%). 
Dependence of Ad43 infection on CD46 was further 
demonstrated in a similar experiment in which soluble 
CD46 protein (sCD46) was tested as infection inhibitor. 
In this experiment the viruses (Ad35TL or Ad43TL) were 
preincubated with sCD46 prior to be added to cells (CHO 
or CHO-C2). Under these conditions, sCD46 blocked 
92% of CHO-C2 transduction by Ad35TL and 66% of 
transduction by Ad43TL; no inhibition of infection by 
sCD46 was seen in CHO cells (Figure 3B).
An additional proof of CD46 involvement in Ad43 
infection was obtained by infecting CHO and CHO-C2 
cells with Ad43 in the presence of full-sized Ad35 
and Ad43 fibers. Although none of the fibers blocked 
transduction of CHO cells by either virus (Figure 3C), 
transduction of CHO-C2 cells by Ad43 was inhibited 
by the Ad35 fiber but not by the Ad43 fiber. These data 
confirmed our initial findings of the CD46-dependence 
of Ad43 infection and also showed that, at the tested 
concentrations, the free Ad43 fiber is unable to compete 
for CD46 attachment with the virion-associated fibers. The 
inefficient inhibition of Ad43 infection of CHO-C2 cells 
with the recombinant Ad43 fiber knob protein provided 
additional evidence of the fiber’s inability to compete: 
the knob did not inhibit infection of CHO-C2 cells at 
100 mg/ml and caused only moderate inhibition (55%) at 
the very high concentration of 1 mg/ml (Figure 3D).
The Ad35 fiber’s knob is known to have very high 
affinity for CD46 [29] and is thus a strong competitor. The 
incomplete inhibition of Ad43 infection by the CD46-
binding Ad35 fiber and its knob suggested that molecules 
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Figure 2: Lack of interaction between Ad43 virions and FX results in minimal hepatic transduction, but does not affect 
the vector uptake by the liver. (A) Surface plasmon resonance analysis of FX interaction with Ad43 and Ad5. Sensorgrams obtained 
by probing chip-immobilized Ad virions with soluble FX are shown in duplicates, each curve corresponding to a separate run. Serial two-
fold dilutions of FX covered a range of concentrations from 0.4 µg/ml (shown in light blue) to 25 µg/ml (shown in red). The calculated 
K
D
 for Ad5-FX interaction is 1.50 × 10−9 M. (b) Overlays of the whole-body bioluminescent and X-ray images of groups of mice (n = 3) 
intravenously injected with Ad5TL and Ad43TL vectors (4 × 1010 viral particles [VP] each) acquired 48 h after injections. The regions of 
interest that outline the livers are shown with red frames. The levels of bioluminescence measured in these regions of interest (total flux, 
photon/s) are shown below the images of mice. The pseudo-colour scale shows the radiance in photons/second/centimeter2/radian2. (c) The 
activity of the Fluc reporter measured in the homogenates of organs collected from Ad-injected mice 72 h after vectors injections. Each bar 
represents an average signal intensity in relative light units (RLU) per entire organ. Error bars indicate the standard deviations for a group of 
three animals; the measurements were taken in duplicates. The Fluc activities in PBS-injected mice were (in RLU/organ): 1.9 × 107 (liver), 
5 × 106 (spleen), 9.9 × 105 (lung), 1.2 × 106 (heart), 3.4 × 106 (kidney). *p ˂ 0.05, **p ˂ 0.01, ***p ˂ 0.001. (D) The copy numbers of viral 
genomes shown here were measured using qPCR in organs isolated from mice 1 h, 24 h, or 72 h after injections with Ad5TL or Ad43TL 
(4 × 1010 VP). In panels (C and D) each bar represents an average copy number of viral genomes per organ and error bars show the standard 
deviations for each group animals (n = 3). P values for panel (D) are presented in the main text.
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other than CD46 may function as alternative receptors for 
Ad43. This possibility was supported by previous reports 
on the use by some Ads of more than one type of molecule 
as a primary receptor. For example, CD46, CD80, CD86, 
and desmoglein 2 were identified as receptors for Ad3 
[30–32]. 
We also knew that Ad9, a member of species D, uses 
its penton base protein to attach directly to integrins and 
achieve successful infection, thereby obviating the need 
for fiber-receptor interaction [16, 33]. To test whether 
a similar cell attachment mechanism is used by Ad43, 
virus binding to integrins on CHO and CHO-C2 cells was 
blocked by pretreating the cells with an RGD-containing 
peptide or EDTA prior to infection with Ad43TL. Under 
these conditions, both inhibitors blocked more than 
80% of Ad43 transduction of each cell line, suggesting 
that, irrespective of CD46 expression, the virus can use 
integrins for attachment and infection (Figure 3E). 
Modification of Ad43’s primary receptor 
specificity using an Ad43/5 fiber chimera  
yields a Her2-specific vector unaffected by  
Ad5-neutralizing antibody
The fact that Ad43 uses at least two types of broadly 
expressed receptors for infection makes targeted therapy 
with Ad43-based vectors unlikely unless the virus can be 
made target-specific. As a first step in this direction, we 
wished to test the feasibility of such tropism modification 
by directing Ad43 to human epidermal growth factor 
receptor type 2 (Her2), a known tumor biomarker, by 
modifying the virus’ fiber protein. The previous reports 
on the importance of Ad fiber length and flexibility to 
efficient transduction [2, 3] and the shortness and predicted 
rigidity of the Ad43 fiber revealed by our sequencing data 
collectively suggested that successfully targeting this fiber 
may require elongation and engineering of additional 
flexibility. To these ends, we designed four Ad43 fiber-
derived, Her2-targeted chimeras each containing the 
amino-terminal tail domain of the Ad43 fiber (aa 1–48), 
the carboxy-terminal domain of the fragment of phage T4 
fibritin protein that comprises the last two a-helical repeats 
of the stalk and the foldon domain (aa 393–487, GenBank 
accession number L43611), the (Gly
4
Ser)
3
 linker, and the 
Her2-specific affibody Z
her2:7 
[34] (Figure 4A). The central 
domain contained a non-modified Ad43 shaft (Ad43 fiber 
aa 49–180) in a F
43
11F
Her2:7
 chimera, an Ad43 shaft with 
its 3rd repeat (Ad43 fiber aa 76–90) replaced with the 
3rd repeat of the Ad5 fiber shaft (Ad5 fiber aa 74–94) in 
F
43M1
11F
Her2:7
, an Ad43 shaft with insertion of a TTVS-
tetrapeptide between V83 and P84 of F
43M2
11F
Her2:7
, and an 
Ad5 shaft (Ad5 fiber aa 50–398) in F
43S5
11F
Her2:
7.
The chimeras and control wild-type (wt) Ad43 
fiber were transiently expressed in 293T cells to compare 
their expression levels and test their binding to Her2 
and self-trimerization—the property essential for fiber 
incorporation in virions. Western blotting of these 
proteins showed significant variations in their expression 
(Figure 4B); it also showed that all non-denatured 
chimeras formed trimers (Figure 4C). Flow cytometry 
in which the Her2-positive 293/Her2 and Her2-negative 
293 cells were probed with these chimeras showed much 
more efficient binding of these proteins to 293/Her2 cells 
than to Her2-negative 293 cells (Figure 4D). However, 
the observed significant decrease in chimeras expression 
was a concern, because it could result in inefficient 
incorporation of these chimeras in Ad43 virions and 
decreased infectivity. Also, low expression of the fiber 
could lead to incomplete maturation of viral proteins 
pVI, pVII, and pVIII, thereby yielding noninfectious 
virions, as has been previously demonstrated for fiberless 
Ad5 [35]. To assess these risks, we first studied the 
dependence of Ad43 fiber incorporation, and virions’ 
maturation, and infectivity on fiber expression efficiency. 
table 1: reporter activity in tissues isolated from Ad-injected mice
Vector 
Liver spleen Lung Heart Kidney
Per 
organa
Per 
gramb
Per 
organ
Per 
gram 
Per 
organ
Per 
gram 
Per 
organ
Per 
gram 
Per 
organ
Per 
gram 
Ad5TL 1.3 × 1013 9.9 × 1012 6.0 × 109 5.8 × 1010 1.8 × 109 7.4 × 109 4.1 × 108 2.9 × 109 1.6 × 109 5.4 × 109
Ad43TL 9.6 × 107 7.2 × 107 6.2 × 107 6.0 × 108 7.9 × 107 3.2 × 108 1.2 × 107 8.1 × 107 1.5 × 108 4.9 × 108
Signal 
ratioc 1.3 × 10
5 1.4 × 105 9.6 × 10 9.7 × 10 2.2 × 10 2.3 × 10 3.3 × 10 3.6 × 10 1.0 × 10 1.1 × 10
PBSd 1.9 × 107 2 × 107 1.5 × 106 1 × 107 9.9 × 105 9.6 × 106 1.2 × 106 9.6 × 106 3.4 × 106 9.6 × 106
a,bActivity of the reporter averaged for groups of three animals is shown in RLUs per entire organ and per gram of tissue. 
cRatio of bioluminescence signals measured in Ad5TL-injected mice to those measured in Ad43TL-injected mice.
dLuciferase activity measured in tissues isolated from phosphate-buffered saline-injected mice.
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To this end, we infected the sublines of the 293-derived 
cell line 293F43 each expressing wt Ad43 fiber at a 
different level (Figure 5A), purified the viral progeny 
(Figure 5B) and characterized it by using western 
blotting (Figure 5C), protein electrophoresis (Figure 5D), 
and transduction of 293 cells (Figure 5E). Importantly, 
this study showed strong correlation between overall 
fiber expression in Ad43-infected cells, on the one 
hand, and both the efficacy of fiber incorporation and 
completeness of virions’ maturation (Figure 5A–5D), 
on the other hand. It also showed, however, that even at 
low levels of fiber production, virus infectivity decreases 
insignificantly (Figure 5E). Together, these findings 
suggested that even at reduced expression levels, the 
fiber chimeras might be able to support Her2-mediated 
infection by the virus.
Figure 3: Ad43 uses cD46 and integrins as primary receptors. (A) The CHO-C2 and CHO cells (CD46-positive and CD46-
negative, respectively) were infected with Ad43TL and Ad35TL vectors. CD46-specific inhibition of transduction by both viruses was 
achieved by blocking the receptor with a recombinant Ad35 knob prior to addition of virus. Here and in panels b–E the activity of the Fluc 
reporter in cell lysates is shown in RLUs as the mean of three replicates; error bars show the standard deviations. (b) Prior to infection 
of CHO-C2 and CHO cells, Ad43TL and Ad35TL were preincubated with sCD46 used here as a competitor of cell-associated CD46. 
(c) The inhibition of Ad43TL transduction with the Ad43 and Ad35 fibers. Prior to infection with Ad43TL, CHO-C2 and CHO cells 
were pre-incubated with the lysates of 293F43, 293F5, or 293 cells expressing the Ad43 fiber (F43), Ad35 fiber (F35), or no fiber (mock), 
respectively. “No inhibitor” bars show the transduction levels seen in the absence of cell lysates. The amount of lysates was normalized 
on the basis of fiber concentrations measured by western blotting. The control cells were infected with the virus in the plain media (no 
inhibitor). Fluc activity was measured in cell lysates 24 h after infection. (D) The inhibition of CHO-C2 cell transduction by the Ad43 
vector with the recombinant Ad43 knob. Prior to being infected with Ad43TL, CHO-C2 cells were incubated with the recombinant Ad43 
knob at concentrations of 100 µg/ml and 1,000 µg/ml. Fluc activity was measured in cell lysates 24 h after infection. (E) The CHO-C2 
and CHO cells were pre-incubated with the integrin-binding GRGDSP-peptide (shown as “RGD”) or EDTA on ice to block binding with 
integrins and then incubated with Ad43TL or Ad35TL (control) on ice to prevent internalization of the virus. The unbound Ad particles were 
removed by washing with ice-cold medium, and the cultures were transferred to 37ºC to allow for internalization of cell-bound virions. No 
pretreatment is shown as “no inhibitor”. After unbound virions were washed away, the cells were incubated at 37ºC to allow virus entry. 
Fluc activity was measured in cell lysates 24 h after infection. *p ˂ 0.05, **p ˂ 0.01.
Oncotarget53420www.impactjournals.com/oncotarget
Once Ad43TL-derived vectors encoding Her2-
targeting chimeras had been prepared, our western 
blotting of these Ads showed that all chimeras 
incorporated in viral particles less efficiently than did 
the wt Ad43 fiber (Figure 6A), correlating with overall 
chimera expression levels, which were reduced 10- to 
100-fold (Figure 6B). Analysis of the viruses’ protein 
composition revealed that all contained significant 
amounts of unprocessed pVI, pVII, and pVIII precursor 
proteins (Figure 6C). These results were in agreement 
with our previous data on the effects of reduced wt Ad43 
fiber expression on virus protein composition; however, 
in contrast to the viruses containing decreased numbers of 
wt Ad43 fibers—which transduced cells quite efficiently 
(Figure 5E)—the chimera-containing viruses showed low 
levels of overall gene transfer, with the Her2-dependent 
component negligible (Figure 6D). This low level of 
Her2-dependent transduction by Ad43TL.F
43S5
11F
Her2:7 
was completely unexpected because Ad43TL.F
43S5
11F
Her2:7 
encoded the chimera that was structurally very similar to 
the Ad5 fiber-based chimera 11F
Her2:7
, which had been 
designed previously and proved fully functional [36]. It 
should be noted, however, that in contrast to F
43S5
11F
Her2:7
, 
the 11FHer2:7 chimera incorporated in Ad5 virions very 
efficiently. The observed 10-fold decrease (compared 
with wt fiber) in F
43S5
11F
Her2:7
 incorporation (Figure 6A) 
Figure 4: Ad43 fiber-derived Her2-targeting chimeras form trimers and bind to Her2. (A) The structure of the Ad43 fiber 
and the Ad43 fiber-derived chimeras. The Ad43 fiber consists of the tail, shaft, and knob domains. The Ad43 fiber shaft is short (8 repeats) 
and it lacks a TTVS hinge motif, whose presence in the third pseudo-repeat of the long Ad5 fiber shaft (22 repeats) make the Ad5 fiber 
flexible. In all chimeras, the tail domain was left intact, whereas the knob domain was replaced with the trimerization domain of phage 
T4 fibritin protein and a Her2-targeting affibody, Zher2:7. The F
43
11F
Her2:7
 chimera contains an unmodified Ad43 fiber shaft. To make the 
chimeras flexible, in F
43M1
11F
Her2:7
, the entire third repeat of the Ad43 fiber shaft was replaced with the third repeat of the Ad5 fiber shaft and 
in F
43M2
11F
Her2:7
, the TTVS hinge was inserted into the Ad43 fiber’s third repeat. To make the chimera flexible and to simultaneously elongate 
it, the Ad43 fiber shaft in F
43S5
11F
Her2:7
 was replaced with the Ad5 fiber shaft. The TTVS hinge is shown in bold; the amino acids in the Ad5 
shaft third repeat that differ from those in Ad43 are underlined. Western blot of boiled (panel b) and non-boiled (panel c) lysates of 293T 
cells transiently expressing the fiber chimeras: F
43
11F
Her2:7 
(lane 2), F
43M1
11F
Her2:7 
(lane 3), F
43M2
11F
Her2:7 
(lane 4), and F
43S5
11F
Her2:7 
(lane 5); the 
wt Ad43 fiber is in lane 1. (Here and in other panels showing the results of western blotting and SDS-PAGE, lane S shows protein standards 
with the molecular masses in kDa). All the chimeras formed trimers but were expressed at lower levels than was the wt Ad43 fiber. The 
predicted molecular masses of monomeric wt Ad43 fiber, F
43
11F
Her2:7
, F
43M1
11F
Her2:7
, F
43M2
11F
Her2:7
, and F
43S5
11F
Her2:7
 are 39.4, 36.8, 37.3, 37.2, 
59.4 kDa, respectively. The image shown in panel 4C has been cropped and regrouped; the lane showing protein standards was digitally 
enhanced. (D) Flow cytometry of Her2-positive and negative cells probed with the designed fiber chimeras. The protein probes are: wt Ad43 
fiber (control), 1; F
43
11F
Her2:7
, 2; F
43M1
11F
Her2:7
, 3; F
43M2
11F
Her2:7
, 4; F
43S5
11F
Her2:7
, 5; lysate of mock transfected 293T cells, M. 
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meant that, on average, an Ad43TL.F
43S5
11F
Her2:7
 particle 
contained only 1.2 copies of the chimera. Calculations 
using a binomial distribution model predicted that 28% 
of virions in the preparation contained no fibers, 38% and 
23% contained one or two fibers, respectively, and less 
than 0.06% contained six fibers or more. 
To see whether efficient Her2-dependent 
transduction by an Ad43 vector could be achieved by 
increasing the expression of F
43S5
11F
Her2:7
, we generated 
a 293F
43S5
11F
Her2:7
 cell line stably expressing this 
chimera at a high level. The Ad43TL.F
43S5
11F
Her2:7
 vector 
was remade by infecting these cells with Ad43TL.ΔF 
Figure 5: Characterization of the Ad43TL virions amplified in cell lines stably expressing the Ad43 fiber at various 
levels. (A) Western blot of the lysates of 293F43 clones expressing the wt Ad43 fiber. Lane 1, clone 20 with a maximal level of fiber 
expression (set at 100%); lanes 2, 3 and 4, clones 7, 3, and 2, respectively, each expressing the fiber at 38%, 18% and 7% of expression in 
clone 20, respectively. (b) The appearance of the viral bands after the first (upper row) and second (lower row) centrifugation in CsCl.  The 
tubes 1, 2, 3, and 4 contain samples of Ad43TLΔF amplified in 293F43 clones 20, 7, 3, and 2, respectively. Only the sample obtained from 
clone 20 produces the expected banding patterns. The arrow on the right points at additional, higher-density bands in viral preparations 
obtained from clonal lines 7, 3, and 2. The bracket shows an area of the gradient containing a diffuse area corresponding to heterogeneous 
viral particles isolated from line 2. Western blot (panel c) and silver staining (panel D) of purified virions  (1010 VP) shown in panel B. 
The Ad43TLΔF virions propagated in clones with lower levels of fiber expression contain fewer fibers (as seen in panel C) and more 
unprocessed precursors of the proteins pVI, pVII, and pVIII (panel D). Lanes 1-4, viruses collected from tubes 1–4 (as shown in panel B), 
respectively. The Ad43 structural proteins and their predicted migration positions are shown on the right of panel D. Here and in Figures 6 
and 7, F43 indicates wt Ad43 fiber. Panels A–D show cropped images. (E) Gene transfer by purified viruses. Shown are the activities of 
Fluc in lysates of 293 cells infected with viruses at an MOI of 100 VP/cell (n = 3), which were measured 24 h after infection.  Error bars 
indicate the standard deviations. *p ˂ 0.05.
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previously amplified in wt Ad43 fiber-expressing 293F43 
line 20 cells. The increased expression of the chimera in 
293F
43S5
11F
Her2:7
 cells yielded Ad43 particles that contained 
F
43S5
11F
Her2:7
 at the level of 49% of wt Ad43 fiber in 
control Ad43TL particles (Figure 7A). Also, compared 
to the Ad43TL.F
43S5
11F
Her2:7
 virions previously obtained 
from 293A cells (Figure 6C), this new preparation of 
vector contained much lower amounts of unprocessed 
pVI, pVII, and pVIII precursor proteins (Figure 7B). As 
a result of these improvements, the virus gained an ability 
to transduce cells efficiently and in a Her2-dependent 
manner; gene transfer to 293/Her2 cells was 72-times 
more efficient than transfer to 293 cells, and 3-times more 
efficient than by unmodified control Ad43TL (Figure 7C). 
The advantage of Ad43TL.F
43S5
11F
Her2:7
 over Ad43 vector 
with native tropism was also shown using Her2-expressing 
tumor cell lines MDA-MB-231/Her2, SKOV3.ip1, and 
SKBR3 Figure 7D). In this instance, the Her2-dependence 
of gene transfer was confirmed by selective inhibition of 
transduction with a free Her2-binding affibody competitor. 
Importantly, the presence of a rather large Ad5-
derived protein domain—the Ad5 fiber shaft—in Ad43TL.
F
43S5
11F
Her2:7
 particles has not made this Ad43 vector 
susceptible to neutralization by anti-Ad5 Abs (Figure 7E), 
suggesting that the Ad43 antigenic profile remains largely 
unchanged despite the presence of the Ad5 fiber shaft.
DIscUssION
Extensive epidemiological studies identified the 
preexisting humoral immunity to Ad5 found in many 
humans as one of the major limitations of Ad5-based 
gene therapy [9]. In addition, the strong immunogenicity 
of Ads and the need to administer vectors repeatedly to 
achieve clinically relevant outcomes strongly suggest that 
a successful gene therapy strategy based on a single Ad 
serotype is unlikely. This is because even in the absence 
of preexisting anti-Ad Ab, in response to vector injection 
the anti-vector humoral immunity builds quickly thus 
making successive rounds of therapy inefficient [37]. 
Therefore, the need for vectors with different antigenic 
profiles is apparent. The natural serodiversity of Ads 
and significant differences in Ads’ seroprevalence in 
humans provide a rationale for designing vectors with 
altered antigenicity [13]. Importantly, the molecular 
diversity of Ad serotypes, which results in differential 
modes of Ad vector interaction with host tissues, 
may be used to solve the problem of off-target gene 
delivery by Ads and its resulting toxicity. For instance, 
previous studies have shown that the undesired hepatic 
transduction and toxicity of Ad5-based vectors can be 
significantly reduced by developing inter-serotype hexon 
chimeras [10, 11]. 
Figure 6: Ad43 vectors encoding chimeric fibers incorporate them at reduced efficiency, contain unprocessed precursor 
proteins, and poorly transduce Her2-expressing cells. In all panels: 1, Ad43TL; 2, Ad43TL.F
43
11F
Her2:7
; 3, Ad43TL.F
43M1
11F
Her2:7
; 4, 
Ad43TL.F
43M2
11F
Her2:7
; 5, Ad43TL.F
43S5
11F
Her2:7
. Western blot of purified viruses (panel A) and lysates of 293A cells infected with the fiber-
modified viral vectors (panel b). Shown are percentages of the chimeras’ incorporation and expression relative to those of wt Ad43 fiber (set 
at 100%). (c) SDS-PAGE gel (silver stained) of purified viruses. Arrowheads indicate the positions of chimeras F
43
11F
Her2:7
, F
43M1
11F
Her2:7
, 
and F
43M2
11F
Her2:7
. (D) The gene transfer to 293/Her2 and 293 cells with purified viruses. The cells were infected with purified viruses at 
an MOI of 100 VP/cell.  Mean values for Fluc activity (n = 3) in cells 24 h after infection are shown. Error bars indicate the standard 
deviations. *p ˂ 0.05.
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In this regard, our study of Ad43 interaction with FX 
and patterns of gene transfer on Ad43 vascular delivery 
provide additional evidence of an emerging concept that 
links weak or nonexistent FX binding by a given Ad with 
very low hepatic transduction by that virus. In agreement 
with recent reports [4–6], we have shown that Ad43’s 
inability to cause liver transduction correlates well with 
its failure to associate with FX. Interestingly, comparison 
of Ad43’s hexon structure with those of other Ads could 
not reliably predict the strength of Ad43-FX interaction; 
although the absence of key amino acids known to mediate 
such binding was predictive of a lack of binding, the 
presence of a putative FX binding-enabling TDT motif 
suggested otherwise. Our data clearly show that the mere 
presence of TDT motif in the hexon is not sufficient to 
enable FX binding. Supporting further development of 
Ad43-derived therapeutic vectors, the discovery of TLR/
NF-kB-mediated innate immunity activation following 
cellular uptake of Ad-bound FX [12] suggests that the 
magnitude of this immune response to FX-nonbinding 
Ad43 and associated toxicity should be lower than 
responses triggered by Ad5 vectors.
Whereas the level of random transduction by 
systemic Ad43 was very low, we found the level of virus 
sequestration by the liver to be high. This is most likely 
owing to virus uptake by Kupffer cells—a mechanism 
well-established for every Ad serotype tested to date [4, 7]. 
Therefore, future development of Ad43 as a truly targeted 
vector will require ablation of its recognition by Kupffer 
cells—a universal Ad-vector development problem for 
which a satisfactory solution applicable to humans is yet 
to be found.
Of importance to potential clinical use of Ad43-
based gene vectors is the observed accelerated clearance 
of this virus from the host’s tissues. Although the 
molecular mechanisms underlying this clearance are yet 
to be identified, it is reasonable to speculate that in certain 
clinical scenarios this clearance may offer the advantage of 
a more time-limited genetic intervention than is possible 
with Ad5-based vectors.
We found that Ad43 can use two alternative 
receptors—CD46 and integrins—for infection. Together 
with the previous reports on Ad3, Ad5, Ad9, and Ad49 
[14, 16, 30–32, 38, 39], this finding establishes the use 
Figure 7: Increased expression of the F43s511FHer2:7 chimera yields an Ad43 vector that is capable of efficient Her2-
specific transduction and is not neutralized by anti-Ad5 Abs. The western blotting (panel A) and SDS-PAGE (panel b) of 
CsCl-purified virions (1010 VP/lane) of Ad43TL.F
43S5
11F
Her2:7
 amplified in 293F
43S5
11F
Her2:7 
cells (lane 1), and Ad43TL (lane 2). FC, the 
F
43S5
11F
Her2:7
 fiber chimera. The images shown in panel 7A and 7B have been cropped and regrouped. The gene transfer to 293/Her2 and 293 
cells (panel c), and tumor cell lines expressing Her2 (panel D). The Zher2-7 affibody was used as a Her2-specific inhibitor (panel D only). 
Ad43TL.F
43S5
11F
Her2:7
, 1; Ad43TL, 2. The Her2-negative MDA-MB-231 cells, a parental line for Her2-expressing MDA-MB-231/Her2 
cells, are shown as a control. (E) In vitro vector neutralization assay. The sera obtained from naïve or Ad5-immunized mice were added to 
293/Her2 cells prior to transduction with Ad5TL or Ad43TL.F
43S5
11F
Her2:7
 vectors. The levels of transgene expression in transduced cells 
relative to expression level seen in the absence of serum are shown. The sera dilution factors are shown below the graphs. NS, no serum. In 
panels C, D, and E, data are shown as the mean of three replicates; error bars show the standard deviations. *p ˂ 0.05, **p ˂ 0.01.
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of alternative cell entry pathways by an Ad serotype as 
an important evolutionary accomplishment that results in 
virus’ enhanced infectivity, propagation, and survival. 
The drastic difference in efficacy with which the 
Ad35 and Ad43 fiber knobs inhibited Ad43 infection 
that we observed is likely due to the differing affinities 
these knobs have for CD46. Supporting this explanation 
is the fact that, of all the Ad fiber knobs tested, the Ad35 
knob is one of the tightest binders of CD46 (equilibrium 
dissociation constant, K
D
, of 16 nM [29]; K
D
s in the 
nanomolar range have been reported for other CD46-
binding Ad fiber knobs [29, 40]). The poor inhibition 
of Ad43 transduction by the Ad43 fiber and its knob 
also suggests that their affinity for CD46 is too low for 
successful competition with the virus-associated fibers in 
which receptor-binding efficacy is dramatically enhanced 
by avidity. The gains of such cooperative binding to an Ad 
receptor have previously been shown for Ad3 [32], whose 
knob binds to desmoglein 2 with a very low affinity (K
D
 
of 10 mM) [41]. Also, these gains are realized by the low-
affinity CD46-binders Ad21 and Ad16 (K
D
s of 284 nM and 
437 nM, respectively [40, 42]).
The high-avidity binding of Ads to primary receptors 
via low-affinity fibers has important practical implications 
for the development of targeted Ad vectors because it 
indicates that the affinity of a targeting ligand for a desired 
receptor does not have to be very high to support efficient 
infection. The feasibility of such relatively low affinity 
targeting of Ad5 has been demonstrated using the weakly 
binding Ad3 knob [43] and by modifying the tropism 
of Ad5 and simian Ad24 (sAd24), with a low-affinity 
affibody ligand [4, 36].
Importantly, our identification of CD46 as the 
primary receptor for Ad43 does not call into question the 
validity of our biodistribution studies done in mice, which 
don’t express CD46 ubiquitously. This is because several 
in vivo studies of unmodified Ad virions in mice have 
convincingly shown that the observed virus distribution 
patterns are determined by the interactions of Ad virions 
with FX [5, 6, 10, 44], scavenger receptors on Kupffer 
cells, natural Abs, and complement [45] in which the Ad 
fiber’s receptor specificity plays no known role. Given 
these findings, studying the biodistribution of unmodified 
Ad43 virions in CD46-expressing transgenic mice [46–48] 
does not seem to offer real benefits.
Applying the fiber knob replacement targeting 
approach [49] to Ad43 in this study revealed some of the 
limitations of this strategy: in contrast to Ad5 and sAd24 
previously targeted using this strategy [4, 36], Ad43 
could not be targeted to Her2 by simple replacement of 
its knob domain with the fibritin-affibody fusion. The 
predicted rigidity of the Ad43 fiber is an unlikely cause 
of this problem, because insertion of a flexible hinge 
did not rectify the chimera’s deficiency. The desired 
tropism modification of Ad43 was successful only after 
replacement of the rigid and short Ad43 fiber shaft with a 
flexible and long Ad5 fiber shaft, suggesting that the length 
of the chimera (rather than its flexibility) is essential for 
Her2-dependent infection. Given the relatively low 
affinity of the Zher2-7 affibody for Her2 (K
D
=140 nM 
[34]), binding of Ad43 to Her2 may require simultaneous 
engagement of several ligands by a single Ad virion. In 
this scenario, the density of Her2 molecules on the cell 
surface may favor receptor cross-linking and infection 
only by a virus with long fibers. Notably, incorporation of 
the Ad5 fiber-derived domain in the targeted Ad43 vector 
did not compromise the virus’ antigenic profile because 
the vector’s infectivity was unaffected by Ad5-neutraling 
Abs. Therefore, the therapeutic derivatives of this vector 
prototype would face little risk of neutralization in patients 
with preexisting anti-Ad5 Abs.
In conclusion, this study showed that systemically 
delivered Ad43 demonstrates low levels of random 
transduction and relatively quick clearance from the host 
tissues. It also demonstrated the feasibility of manipulating 
the virus’ specificity for primary receptor while retaining 
Ad43’s unique antigenicity. Together with the previously 
reported low seroprevalence of Ad43 in humans, these 
findings identify this virus a promising candidate for 
future development of gene therapy vectors. 
MAtErIALs AND MEtHODs
sequencing of the Ad43 genome, genome 
annotation, and global pairwise alignment
The stock of Ad43 was purchased from the 
American Type Culture Collection, ATCC (Manassas, VA, 
catalog #VR-1305). Viral DNA isolated from the virus 
amplified in 293 cells was sequenced and the reads were 
assembled using ContigExpress component of Vector NTI 
software (Life Technologies, Carlsbad, CA). The J. Craig 
Venter Institute Annotation Service analyzed the resultant 
contig using their adenovirus automated annotation 
algorithm based on homology predictions (http://gsc.jcvi.
org/projects/gsc/adenovirus/index.php). A global pairwise 
sequence comparison of Ad43 with other human Ads 
was performed using the sequence alignment program 
mVISTA LAGAN (http://genome.lbl.gov/vista/mvista/
submit.shtml). The GenBank accession numbers for 
analyzed viral genomes are shown in Supplementary 
Figure S1. 
cells and reagents
Human embryonic kidney 293 and 293T cells, 
Chinese hamster ovary CHO cells, and breast carcinoma 
SK-BR-3 cells were obtained from the ATCC. 293A cells 
were obtained from Life Technologies. Human breast 
MDA-MB-231 and ovarian SKOV3.ip1 carcinomas were 
provided by Janet Price (MD Anderson Cancer Center, 
Houston), and CHO-C2 cells that express the C2 isoform 
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of CD46 were provided by Andre Lieber (University of 
Washington, Seattle). 293/Her2 and MDA-MB-231/Her2 
cells were developed in our laboratory [4, 36].  All cell 
lines were maintained as recommended by the vendor or 
as previously reported. The cells were authenticated at M. 
D. Anderson’s Characterized Cell Line Core Facility using 
Short Tandem Repeat (STR) method. The cultures were 
tested for mycoplasma contamination monthly.
293F43 and 293F
43S5
11F
Her2:7 
cell lines constitutively 
expressing the wt Ad43 fiber or F
43S5
11F
Her2:7
 chimera were 
derived from 293 cells by transfection with pFXhAd43 
and pFusion27
43S5
 plasmids, respectively, and selection on 
G418. The level of fiber expression in selected clones was 
quantitated using western blotting of cell lysates with anti-
fiber mouse Ab 4D2 [50].
RGD-containing peptide (GRGDSP) was obtained 
from Sigma (St. Louis, MO). The Ad35 fiber knob 
protein was a gift from Andre Lieber. The Z
her2-7 
affibody 
and anti-Ad5 neutralizing Ab were produced as reported 
previously [4, 51]. The Ad43 knob protein was expressed 
in Escherichia coli using pET20b plasmid vector (EMD 
Millipore, Billerica, MA) and purified by chromatography 
using the protocols reported previously [52]. Recombinant 
soluble human CD46 protein comprising the extracellular 
component of the receptor was produced and purified as 
previously described [53].
Genetic engineering
The cloning schemas, DNA maps, and sequences of 
the fiber- and fiber chimeras- expressing plasmids for the 
generation of 293F43 and 293F
43S5
11F
Her2:7
 cell lines and 
transient protein expression; the shuttle plasmids for the 
E1 region replacement; the fiber and fiber chimeras shuttle 
plasmids; and the rescue plasmids containing Ad genomes 
are available upon request.
Viruses
The genomes of recombinant Ad43 and Ad35 
vectors were assembled in rescue plasmids using 
homologous recombination in Escherichia coli strain 
BJ5183 between the corresponding shuttle and rescue 
plasmids, as previously described [36]. The genes of the 
E1 regions within these genomes were replaced with a 
CMV promoter–driven expression cassette containing the 
TL transgene, which encodes a genetic fusion of the herpes 
simplex virus thymidine kinase and firefly luciferase, and 
the E4 orf6 were replaced with the Ad5 E4 orf6. The Ad 
genomes were released from the corresponding rescue 
plasmids by restriction endonuclease digestion and used 
for transfection. The viruses containing wt fibers were 
rescued in 293 cells and then propagated in 293A cells. 
The Ad43 vectors with chimeric fibers were initially 
rescued and propagated in 293F43 line 20. This yielded 
mosaic virions containing both the wt and chimeric fibers. 
To obtain vector preparation containing only the chimeric 
fibers, 293A cells were infected with these mosaic viruses. 
These infections were done at the same multiplicity of 
infection (MOI) of 3 infectious units (IU)/cell using 
infectious titers of mosaic Ad preparations determined in 
293A cells by spot assay [54]. In brief, 293A cells seeded 
in 24-well plates were infected with serial dilutions of 
viral preparations, the infection was allowed to develop 
for 24 h, the individual cells in which productive infection 
has developed were identified by staining with anti-hexon 
Ab and counted.
The construction of Ad5TL-an E1-deleted Ad 
vector expressing a dual reporter gene TL-was previously 
described [36].
All Ads were purified by centrifugation in CsCl 
gradients, dialyzed against a buffer containing 10 mM 
Tris (pH 8.0), 50 mM NaCl, 2 mM MgCl, and 10% 
glycerol, and stored at -80°C. The particle titers of viral 
preparations were determined by measuring the total 
protein concentration, as previously described [36]: 1 mg 
of total Ad protein per milliliter was considered equivalent 
to 4 × 1012 VPs/ml.
surface plasmon resonance
Biosensor studies in which Ad virions were probed 
with human FX were performed essentially as described 
in our recent report [4]. 
studies in mice and experiments using murine 
tissues
All experiments involving animals were done 
according to protocols approved by the Institutional 
Animal Care and Use Committee of The University of 
Texas MD Anderson Cancer Center and followed National 
Institutes of Health and United States Department of 
Agriculture guidelines. 
 To study the in vivo patterns of transgene expression 
by Ad vectors, 6- to 8-week-old female NCr nu/nu mice 
(Taconic, Hudson, NY) were injected intravenously (tail 
vein) with either phosphate-buffered saline (PBS) or 
4 × 1010 VPs in 100 µl of PBS. Forty-eight hours later, 
the mice were anesthetized by isoflurane inhalation and 
injected in the tail vein with a solution of D-luciferin 
(Caliper, Hopkinton, MA). The optical and X-ray images 
of mice were acquired using IVIS Lumina XR imaging 
system (PerkinElmer, Waltham, MA) and overlaid using 
Living Image software version 4.3 (PerkinElmer). The 
bioluminescence signals measured within the selected 
regions of interest were analyzed using Living Image 
software. 
Twenty-four hours later, the mice were euthanized 
by CO
2
 inhalation, individual organs were collected, and 
homogenized. Aliquots of homogenized tissues were 
lysed in reporter lysis buffer (Promega, Madison, WI) 
and Fluc activity in supernatants was measured in a Sirius 
luminometer (Berthold, Pforzheim, Germany) using the 
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luciferase assay system (Promega). The Wilcoxon rank-
sum test was used to compare reporter activities by each 
vector for each tissue type using SAS 9.2 software (SAS 
Institute, Cary, NC).  
To establish patterns of biodistribution of Ad 
particles, the mice were injected intravenously (tail 
vein) with 4 × 1010 VP of one of the tested Ads and 
killed at 1 h, 24 h, or 72 h after injection. After perfusion 
of animals with heparin-containing PBS, the tissue 
collection and lysis were performed. The 100-fold 
dilutions of tissue lysates in water were used as templates 
for quantitative PCR. Ad genomes were detected using 
primers and 6-carboxyfluorescein (6FAM)-labeled probes 
complementary to the E4 region and DNA polymerase 
gene, respectively. Reactions were run in an ABI 7500 
instrument and the data were processed using ABI 7500 
software (Life Technologies). Generalized linear models 
were used to predict and contrast the log10 copy numbers 
of viral DNA using tissue type, time point, and vector type. 
The Kruskal-Wallis test was used to compare Ad DNA 
copy numbers between time points separately by virus and 
tissue type. No adjustment for multiplicity was made.  
In vitro gene transfer
Transduction of cells was performed as previously 
described [4]. Briefly, cells were incubated for 10 minutes 
with either medium alone or medium containing affibody, 
recombinant knobs, sCD46, or lysates of cells expressing 
fibers. Lysates of the fiber-expressing cells were prepared 
by three freeze-thaw cycles and the fiber concentration 
in the lysates was determined by western blotting and 
normalized prior to incubation with the cells. Next, the 
cells were infected for 30 minutes with one of the Ad 
vectors. The medium was replaced with fresh medium and 
incubation was continued for 24 hours, after which the 
cells were lysed using reporter lysis buffer (Promega). Fluc 
activity in cell lysates was measured as described above.
In gene transfer experiments involving RGD-peptide 
and EDTA, the cells were incubated with RGD-peptide or 
treated with EDTA (2 mg/ml and 10 mM, respectively) in 
DMEM/F12 on ice for 1 h, and then Ad vectors diluted in 
4% FSC-DMEM/F12 were added and cells were incubated 
on ice (to prevent virus internalization) for another hour. 
The unbound virus was removed by washing with the ice-
cold medium and the cells were transferred to 37˚C to 
allow virus internalization.
In the virus neutralization assay, the viruses were 
mixed with anti-Ad5 mouse serum that had been diluted 
in PBS prior to being added to cells.  
Flow cytometry
Cell attachment by the targeted fiber was detected 
according to the previously described protocol [36]. In brief, 
the cells were incubated with aliquots of cleared lysates of 
293T cells either mock-transfected or transfected with the 
plasmid that expresses the fiber (wt or chimeric). The cell-
bound fibers were detected with 4D2 mAbs and secondary 
goat anti-mouse IgG Ab labeled with Alexa Fluor 488 (Life 
Technologies). Cells were analyzed using a FACSCalibur 
instrument (BD Biosciences, Franklin Lakes, NJ).
Western blotting and silver staining
The fiber proteins in cell lysates were analyzed by 
western blotting as previously reported [55]: the blotting 
membranes were probed with monoclonal anti-fiber Ab 
4D2 [50] followed by labeled goat anti-mouse IgG Ab 
conjugated with near-infrared fluorescence dye IRDye800, 
the membranes were scanned in Odyssey scanner 
(Li-COR, Lincoln, NE) and images were processed using 
Image Studio 2.0 software. To determine the protein 
composition of the virions, samples containing 1010 
purified VP were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and the 
gels were stained using a PageSilver silver staining kit 
(Thermo Fisher Scientific, Waltham, MA) according to 
the manufacturer’s recommendations. 
statistical analysis
In the virus biodistribution studies, Wilcoxon rank-
sum and Kruskal-Wallis tests were used to compare 
virus copy numbers by tissue type, virus, and/or time 
point. These analyses were performed using SAS 9.2 for 
Windows (SAS Institute Inc., Cary, NC). To predict the 
percentage of Ad43 virions incorporating various numbers 
of F
43S5
11F
Her2:7
 chimera, calculations were done using a 
binomial distribution model. The reporter expression data 
and western blotting data on the expression of the Ad43 
fiber and fiber chimeras were processed using analysis of 
variance (ANOVA) and the Tukey procedure to adjust for 
multiple comparisons.
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